公开(公告)号：US11906519B2

公开(公告)日：2024-02-20

申请号：US16321745

申请日：2017-07-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng Zhang ,  Zhiqiang An ,  Ningyan Zhang ,  Mi Deng ,  Jaehyup Kim ,  Xun Gui

IPC: G01N33/574 ,  G01N15/14 ,  G01N21/64 ,  G01N33/50 ,  G01N33/49 ,  G01N15/00 ,  G01N15/10

CPC classification number: G01N33/57426 ,  G01N15/14 ,  G01N21/6428 ,  G01N21/6456 ,  G01N33/4915 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2015/0065 ,  G01N2015/1006 ,  G01N2021/6439

Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

公开(公告)号：US11174320B2

公开(公告)日：2021-11-16

申请号：US16441350

申请日：2019-06-14

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan Zhang ,  Zhiqiang An

IPC: C07K16/32 ,  G01N33/574 ,  A61F7/10 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K39/00

Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

公开(公告)号：US20210253680A1

公开(公告)日：2021-08-19

申请号：US17146187

申请日：2021-01-11

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jean X. Jiang ,  Zhiqiang An ,  Ningyan Zhang ,  Wei Xiong ,  Manuel A. Riquelme ,  Sumin Gu ,  Naomi Ledene Sayre

IPC: C07K16/18 ,  A61P25/28 ,  A61K39/395 ,  A61P35/00 ,  A61P19/10

Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening arc provided.

公开(公告)号：US10975142B2

公开(公告)日：2021-04-13

申请号：US16244097

申请日：2019-01-09

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Philipp Erich Scherer ,  Jiyoung Park ,  Zhiqiang An

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/46 ,  C07K16/00 ,  C07K16/18 ,  A61K33/24 ,  A61K31/555

Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.